Tocagen to Report First Quarter 2019 Financial and Business Results on Tuesday, May 7

SAN DIEGO, April 30, 2019 /PRNewswire/ -- Tocagen Inc. TOCA, a clinical-stage, cancer-selective gene therapy company, today announced it will report its first quarter 2019 financial results and business progress on Tuesday, May 7, 2019, after the close of the U.S. financial markets.

To receive Tocagen's press releases and other investor information, please visit the Investor Relations page of the company's website and register for email alerts.

About Tocagen

Tocagen is a clinical-stage, cancer-selective gene therapy company developing first-in-class, broadly applicable product candidates designed to activate a patient's immune system against their own cancer. Tocagen's lead investigational product candidate, Toca 511 & Toca FC, is under evaluation in a pivotal Phase 3 trial (Toca 5) for recurrent high grade glioma (HGG), a disease with significant unmet medical need. The U.S. Food and Drug Administration awarded Tocagen an orphan drug grant for the Toca 5 trial and has granted Toca 511 & Toca FC Breakthrough Therapy Designation for the treatment of recurrent HGG. The European Medicines Agency has granted Toca 511 PRIME (PRIority MEdicines) designation for the treatment of glioma.

Media Contact:
Pam Lord
Canale Communications
(619) 849-6003
pam@canalecomm.com 

Investor Contact:
Pete Rahmer
Endurance Advisors
(415) 515-9763
prahmer@enduranceadvisors.com

SOURCE Tocagen Inc.

SOURCE Tocagen Inc.